

FORM PTO-1449 (Rev. 1-2001) and B (modified PTO/SB/08)
PATENT & TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 1

APPLICATION NO.:	10/747,855	ATTY. DOCKET NO.:	P0633.70014US01
FILING DATE:	Dec. 29, 2003	CONFIRMATION NO.:	2748
APPLICANT:	Kozhemyakin, et al.		
GROUP ART UNIT:	1654	EXAMINER:	Jeffrey E. Russel

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM/DD/YYYY
		Number	Kind Code		
JER		4,550,022		Garabedian, et al.	10/29/1985
		4,761,399		Pilotto, et al.	08/02/1988
		4,927,808		Kitahara, et al.	05/22/1990
		4,968,671		Asano, et al.	11/06/1990
		5,223,488		Ogata, et al.	06/29/1993
		5,248,697		Wilmore	09/28/1993
		5,916,878		Kolobov, et al.	06/29/1999
		6,013,632		Jones, et al.	01/11/2000
		6,165,979		Kozhemyakin, et al.	12/26/2000
		6,251,857		Kozhemyakin, et al.	06/26/2001
		6,492,329		Kozhemyakin, et al.	12/10/2002

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM/DD/YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
JER		EP	0502313		Clintec Nutrition Company	09/09/1992	
		EP	616803		Holt, John Alfred Gorton	09/28/1994	
		EP	764442		Holt, John Alfred Gorton	03/26/1997	
		WO	92/021368		Life Sciences' Technologies, Inc.	12/10/1992	
		WO	94/00141		Boehringer Mannheim Italia S.P.A.	01/06/1994	
		WO	96/40205		Terrapin Technologies, Inc.	12/19/1996	
		WO	97/21443		Balazovskiy	06/19/1997	
		WO	97/21444		Balazovsky	06/19/1997	
		WO	00/31120		Zakrytoe Aktionernoje Obschestvo	06/02/2000	
		WO	2004/024062		Board of Regents, The University of Texas System	03/25/2004	

EXAMINER: /Jeffrey Russel/ DATE CONSIDERED: 07/18/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]



FORM PTO-1449/A and PTO-89 (modified PTO/SB/08)				APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 29, 2003	CONFIRMATION NO.: 2748
				APPLICANT: Kozhemyakin, et al.	
Sheet	1	of	6	GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
JER		5,206,220		Hilton	04/27/1993
		5,208,249		Rowe, et al.	05/04/1993

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
JER		JP	10-59839				(abstract)
		JP	62-221698				(abstract)
		JP	4-9336				(abstract)

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
JER		Ahmed, K.A., et al., "Nonenzymic Reactivation of Reduced Bovine Pancreatic Ribonuclease by Air Oxidation and by Glutathione Oxidoreduction Buffers," <i>The Journal of Biological Chemistry</i> , Vol. 250, No. 21, pp. 8477-8482 (1975).	
		Araie, M., et al., "Effect of Oxidized Glutathione on the Barrier Function of the Corneal Endothelium," <i>Investigative Ophthalmology & Visual Science</i> , Vol. 29, pp. 1884-1887 (1988).	
		Aukrust, P., et al., "Increased Levels of Oxidized Glutathione in CD4 ⁺ Lymphocytes Associated With Disturbed Intracellular Redox Balance in Human Immunodeficiency Virus Type 1 Infection," <i>Blood</i> , Vol. 86, No. 1, pp. 258-267 (1995).	
		Barbato, G., et al., "Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain," <i>The EMBO Journal</i> , Vol. 19, No. 6, pp. 1195-1206 (2000).	
		Barot-Ciorbaru, R., et al., "Immunomodulators from Nocardia opaca," <i>Forum on immunomodulators</i> , pp. 63-77 (1995).	
		Beckett, G. J., et al., "Glutathione S-Transferases: Biomedical Applications," <i>Advances in Clinical Chemistry</i> , Vol. 30, pp. 281-381 (1993).	
		Beutler, E., "Nutritional and Metabolic Aspects of Glutathione," <i>Annu. Rev. Nutr.</i> , Vol. 9, pp. 287-302 (1989).	
		Blight, K.J., et al., "Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets," <i>Antiviral Therapy</i> , Vol. 3, pp. 71-81 (1998).	
		Bloy, C., et al., "RU 41740 (Biostim), an immunomodulating agent from bacterial origin," <i>Forum on immunomodulators</i> , pp. 85-100 (1995).	
		Bouffard, P., et al., "An in Vitro Assay for Hepatitis C Virus NS3 Serine Proteinase," <i>Virology</i> , Vol. 209, pp. 52-59 (1995).	
		Butkiewicz, N., et al., "Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3," <i>Journal of Virology</i> , Vol. 74, No. 9, pp. 4291-4301 (2000).	
		Butkiewicz, N. J., et al., "Hepatitis C NS3 Protease: Restoration of NS4A Cofactor Activity by N-Biotinylation of Mutated NS4A Using Synthetic Peptides," <i>Biochemical and Biophysical Research Communications</i> , Vol. 267, pp. 278-282 (2000).	

/Jeffrey Russel/

07/18/2006

O I P E
MAY 30 2006
IAP/61
PTO-1449A (07-04-01)
PATENT AND TRADEMARK OFFICE

FORM PTO-1449A and B (modified PTO/SB/08)				APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
				FILING DATE: December 29, 2003	CONFIRMATION NO.: 2748
				APPLICANT: Kozhemyakin, et al.	
Sheet	2	of	6	GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel

OTHER ART — NON PATENT LITERATURE DOCUMENTS

JER	Calabrese, F., et al., "Liver cell Apoptosis in Chronic Hepatitis C Correlates With Historical But Not Biochemical Activity or Serum HCV-RNA Levels," <i>Hepatology</i> , Vol. 31, No. 5, pp. 1153-1159 (2000).
	Carreno, V., et al., "A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B*," <i>Journal of Hepatology</i> , Vol. 32, pp. 317-324 (2000).
	Cerretani, M., et al., "A High-Throughput Radiometric Assay for Hepatitis C Virus NS3 Protease," <i>Analytical Biochemistry</i> , Vol. 266, pp. 192-197 (1999).
	Chen, M., et al., "Human Murine Antibody Recognition is Focused on the ATPase/Helicase, But Not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein," <i>Hepatology</i> , Vol. 28, pp. 219-224 (1998).
	Cirelli, R., et al., "Interferons in human papillomavirus infections," <i>Antiviral Research</i> , Vol. 24, pp. 191-204 (1994).
	Cohen, G., "Enzymatic/Nonenzymatic Sources of Oxyradicals and Regulation of Antioxidant Defenses," <i>Annals New York Academy of Sciences</i> , pp. 8-14. (not dated)
	De Flora, S., et al., "Antioxidant Activity and Other Mechanisms of Thiols Involved in Chemoprevention of Mutation and Cancer," <i>The American Journal of Medicine</i> , Vol. 91, pp. 122-130 (1991).
	Devlin, et al., "Glutathione, Amino Acid Metabolism II: Metabolism of the Individual Amino Acids," <i>Textbook of Biochemistry with Clinical Correlations</i> , 3 rd Edition, pp. 522-528 (1992).
	Dienstag, J. L., et al., "Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States," <i>The New England Journal of Medicine</i> , Vol. 341, No. 17, pp. 1256-1263 (1999).
	Dillman, R. O., "The Clinical Experience with Interleukin-2 in Cancer Therapy," <i>Cancer Biotherapy</i> , Vol. 9, No. 3, pp. 183-209 (1994).
	Droge, W., et al., "Functions of glutathione and glutathione disulfide in immunology and immunopathology," <i>The FASEB Journal</i> , Vol. 8, pp. 1132-1138 (1994).
	Estrela, J.M., et al., "Regulation of glutathione metabolism in Ehrlich ascites tumour cells," <i>Biochem. J.</i> , Vol. 286, pp. 257-262 (1992).
	Fabris, P., et al., "TTV infection in patients with acute hepatitis of defined aetiology and in acute non-A-E hepatitis," <i>Journal of Hepatology</i> , Vol. 32, pp. 661-665 (2000).
	Fan, X.G., et al., "Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection," <i>Mediators of Inflammation</i> , Vol. 7, pp. 295-297 (1998).
	Forman, A., "Neurologic Complications of Cytokine Therapy," <i>Oncology</i> , Vol. 8, No. 4, pp. 105-117 (1994).
	Gallinari, P., et al., "Multiple Enzymatic Activities Associated with Recombinant NS3 Protein of Hepatitis C Virus," <i>J. Virol.</i> , Vol. 72, No. 8, pp. 6758-6769 (1998).
	Galter, D., et al., "Distinct effects of glutathione disulphide on the nuclear transcription factors kB and the activator protein-1," <i>Eur. J. Biochem.</i> , Vol. 221, pp. 639-348 (1994).
	Garaci, E., et al., "Combination therapy with BRMs in cancer and infectious diseases," <i>Mechanisms of Ageing and Development</i> , Vol. 96, pp. 103-116 (1997).
	Gillan, E., et al., "Colony-Stimulating Factors in the Modulation of Sepsis," <i>New Horizons</i> , Vol. 1, No. 1, pp. 96-109 (1993).
	Gillis, D., et al., "Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis," <i>Vaccine</i> , Vol. 18, pp. 3005-3010 (2000).
	Giugliano, D., et al., "Diabetes Mellitus, Hypertension, and Cardiovascular Disease: Which Role for Oxidative Stress?," <i>Metabolism</i> , Vol. 44, No. 3, pp. 363-368 (1995).
	"Glutathione," Unknown Dictionary (Russian) and translation, p. 979. (1961)
	Gregory, C.D., "Apoptosis: a role in neoplasia?," <i>Cell Proliferation</i> , Ch. 13, pp. 342. (not dated)



FORM PTO-1449/4 (A and B) (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet

3

of

6

APPLICATION NO.:	10/747,855	ATTY. DOCKET NO.:	P0633.70014US01
FILING DATE:	December 29, 2003	CONFIRMATION NO.:	2748
APPLICANT:	Kozhemyakin, et al.		
GROUP ART UNIT:	1654	EXAMINER:	Jeffrey E. Russel


OTHER ART — NON PATENT LITERATURE DOCUMENTS

JER	Gruner, N.H., et al., "Association of Hepatitis C Virus-Specific CD8+ T Cells with Viral Clearance in Acute Hepatitis C," <i>The Journal of Infectious Diseases</i> , Vol. 181, pp. 1528-1536 (2000).
	Gwack, Y., et al., "Characterization of RNA Binding Activity and RNA Helicase Activity of the Hepatitis C Virus NS3 Protein," <i>Biochemical and Biophysical Research Communications</i> , Vol. 225, pp. 654-659 (1996).
	Hack, C.E., et al., "C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2," <i>Intensive Care Med.</i> , Vol. 19, pp. S19-S28 (1993).
	Hansson, M., et al., "The Colony Stimulating Factors," <i>Med. Oncol. & Tumor Pharmacother</i> , Vol. 10, No. 1/2, pp. 5-12 (1993).
	Hargrove, M.E., "Regulation by Glutathione of the Activation and Differentiation of IL-4-Dependent Activated Killer Cells," <i>Cellular Immunology</i> , Vol. 149, pp. 433-443 (1993).
	Hayashi, J., et al., "A Relationship between the Evolution of Hepatitis C and Variants, Liver Damage, and Hepatocellular Carcinoma in Patients with Hepatitis C Viremia," <i>The Journal of Infectious Diseases</i> , Vol. 181, pp. 1523-1527 (2000).
	Hieber, U., et al., "Tumor Necrosis Factor for the Treatment of Malignancies," <i>Oncology</i> , Vol. 51, pp. 142-153 (1994).
	Hockenberry, D.M., "Bcl-2 Functions in an Antioxidant Pathway to Prevent Apoptosis," <i>Cell</i> , Vol. 75, pp. 241-251 (1993).
	Holmlund, J. T., "Cytokines," <i>Cancer Chemotherapy and Biological Response Modifiers Annual</i> , Vol. 14, pp. 150-206 (1993).
	Hope, D. B., et al., "A Highly Potent Analogue of Oxytocin, Desamino-oxytocin," <i>The Journal of Biological Chemistry</i> , Vol. 237, No. 5, pp. 1563-1566 (1962).
	Hou-Jun, Y., et al., "N-S phosphoryl migration in phosphoryl glutathion," <i>Int. J. Peptide Res.</i> , Vol. 42, pp. 39-43 (1993).
	Hultgren, C., et al., "The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses," <i>Journal of General Virology</i> , Vol. 79, pp. 2381-2391 (1998).
	Jones, R.J., et al., "Undetectable serum caeruloplasmin in a woman with chronic hepatitis C infection," <i>J. Hepatol.</i> , Vol. 4, pp. 703-704 (2000).
	Kamber, B., et al., "The Synthesis of Cystine Peptides by Iodine Oxidation of S-Trityl-cysteine and S-Acetamidomethyl-cystein Peptides," <i>Helvetica Chimica Acta</i> , Vol. 63, pp. 899-915 (1980).
	Kato, E., et al., "Conversion of Thiols into Disulfides with Diethyl Bromomalonate," <i>Chem. Pharm. Bull.</i> , Vo. 34, pp. 486-495 (1986).
	Kehler, J. P., et al., "Cellular Reducing Equivalents and Oxidative Stress," <i>Free Radical Biology & Medicine</i> , Vol. 17, No. 1, pp. 65-75 (1994).
	Keusch, G. T., "Antioxidants in Infection," <i>J. Nutr. Sci. Vitaminol.</i> , Vol. 39, pp. S23-S33 (1993).
	Knodell Histological Activity Index (web page) last accessed 3/6/01
	Kozhemyakin, L.A., et al., "Glutoxim, a disulfide-containing hexapeptide, ensures a favorable survival outcome and better tolerability of chemotherapy in patients with Stage III-IV non-small-cell lung cancer," <i>Novelos Power Point Presentation</i> , 4 th Annual International Lung Cancer Conference, Greece, 4/27/01
	Krieter, H., et al., "Infusion of Oxidized Glutathione Enhances Postischemic segment-shortening in dog hearts," <i>Cardioscience</i> , Vol. 5, No. 2, pp. 115-126 (1994).
	Kyono, K., et al., "Detection of Hepatitis C Virus Helicase Activity Using the Scintillation Proximity Assay System," <i>Analytical Biochemistry</i> , Vol. 257, pp. 120-126 (1998).

/Jeffrey Russel/

07/18/2006

1010715.1



MAY 30 2006

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
				FILING DATE: December 29, 2003	CONFIRMATION NO.: 2748
				APPLICANT: Kozhemyakin, et al.	
Sheet	4	of	6	GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel

OTHER ART — NON PATENT LITERATURE DOCUMENTS

JER	Lau, D., et al., "Hepatitis G Virus and Human Immunodeficiency Virus Coinfection: Response to Interferon- α Therapy," <i>The Journal of Infectious Diseases</i> , Vol. 180, pp. 1334-1337 (1999).	
	Lee, J.H., et al., "Antiviral Effect of Human Recombinant Interleukin-12 in Patients Infected with Hepatitis C Virus," <i>Journal of Medical Virology</i> , Vol. 60, pp. 264-268 (2000).	
	Li, C., et al., "Complete Regression of Well-established Tumors Using a Novel Water-Soluble Poly(L-Glutamic Acid)-Paclitaxel Conjugate," <i>Cancer Research</i> , Vol. 58, pp. 2404-2409 (1998).	
	Lyttle, M.H., et al., "Isozyme-Specific Glutathione-S-Transferase Inhibitors: Design and Synthesis," <i>J. of Medicinal Chemistry</i> , Vol. 37, pp. 189-194 (1994).	
	Lyttle, M.H., et al., "Glutathione-S-transferase Activates Novel Alkylating Agents," <i>J. Med. Chem.</i> , Vol. 37, pp. 1501-1507 (1994).	
	Malik, A.H., et al., "Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium," <i>Annals of Internal Medicine</i> , Vol. 132, No. 9 (2000).	
	Malnick, S.D., et al., "Treatment of Chronic Hepatitis C Virus Infection," <i>The Annals of Pharmacotherapy</i> , Vol. 34, pp. 1156-1164 (2000).	
	McHutchinson, J.G., et al., "A Pilot Study of Daily Subcutaneous Interleukin-10 in Patients with Chronic Hepatitis C Infection," <i>Journal of Interferon and Cytokine Research</i> , Vol. 19, 1265-1270 (1999).	
	Meister, A., et al., "Glutathione," <i>Ann. Rev. Biochem.</i> , Vol. 52, pp. 711-760 (1983).	
	Meyer, M. et al., " H_2O_2 and antioxidants have opposite effects on activation of NF- κ B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor," <i>The EMBO Journal</i> , Vol. 12, No. 5, pp. 2005-2015 (1993).	
	Michiels, C., et al., "Importance of SE-Glutathione Peroxidase, Catalase, and CU/ZN-SOD for Cell Survival Against Oxidative Stress," <i>Free Radical Biology & Medicine</i> , Vol. 17, No. 3, pp. 235-248 (1994).	
	Missale, G., et al., "Mediatori citochinici nell'infiammazione acuta e nei fenomeni di cronicizzazione delle epatiti virali," <i>Ann. Ital. Med. Int.</i> , Vol. 10, pp. 14-18 (1995). (abstract)	
	Mittelman, M., et al., "Clinical Application of Recombinant Erythropoietin in Myelodysplasia," <i>Hematology/Oncology Clinics of North America</i> , Vol. 8, No. 5, pp. 993-1009 (1994).	
	Morstyn, G., et al., "Hematopoietic growth factors in cancer chemotherapy," <i>Cancer Chemotherapy and Biological Response Modifiers Annual</i> , Vol. 14, pp. 353-370 (1993).	
	Murray, H. W., "Interferon-Gamma and Host Antimicrobial Defense: Current and Future Clinical Applications," <i>The American Journal of Medicine</i> , Vol. 97, pp. 459-467 (1994).	
	Neidhart, J. A., "Hematopoietic Cytokines," <i>Cancer</i> , Vol. 72, No. 11, pp. 3381-3386 (1993).	
	Nelson, D.R., et al., "Interleukin 10 Treatment Reduces Fibrosis in Patients with Chronic Hepatitis C: A Pilot Trial of Interferon Nonresponders," <i>Gastroenterology</i> , Vol. 118, pp. 655-660 (2000).	
	Nelson, S., "Role of Granulocyte Colony-Stimulating Factor in the Immune Response to Acute Bacterial Infection in the Nonneutropenic Host: An Overview," <i>Clinical Infectious Diseases</i> , Vol. 18, pp. 197-204 (1994).	
	Nemunaitis, J., "User of hematopoietic growth factors in marrow transplantation," <i>Current Opinion in Oncology</i> , Vol. 6, pp. 139-145 (1994).	
	Nishida, T., et al., "The Network Structure of Corneal Fibroblasts in the Rat as Revealed by Scanning Electron Microscopy," <i>Investigative Ophthalmology & Visual Science</i> , Vol. 29, pp. 1887-1890 (1988).	
	Offenstadt, G., et al., "Cytokines et etats infectieux graves," <i>Path Biol.</i> , Vol. 41, pp. 820-831 (1993).	
	Pol, S., et al., "Combination of Ribavirin and Interferon-Alfa Surpasses High Doses of Interferon-Alfa Alone in Patients with Genotype-1b-Related Chronic Hepatitis C," <i>Hepatology</i> , Vol. 31, No. 6, pp. 1338-1344 (2000).	



FORM PTO-1449A/1449B (modified PTO/SB/08)				APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
				FILING DATE: December 29, 2003	CONFIRMATION NO.: 2748
				APPLICANT: Kozhemyakin, et al.	
Sheet	5	of	6	GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel

OTHER ART — NON PATENT LITERATURE DOCUMENTS

JER		Polyak, S.J., et al., "The molecular basis for responsiveness to anti-viral therapy in hepatitis C," <i>Forum Trends in Experimental and Clinical Medicine</i> , No. 10.1, pp. 46-58 (2000).	
		Raggi, M.A., "Spectrophotometric determination of thiols in human lymphocytes," <i>Pharmazie</i> , Vol. 53, pp. 239-242 (1998).	
		Raggi, M.A., "Studio della cinetica di reazione tra Pd (II) e glutathione ossidato," <i>Bio. Chim. Parmaccurieo</i> , Vol. 131, No. 8, pp. 318-319 (1992)	
		Renard, D. C., et al., "Oxidized glutathione causes sensitization of calcium release to inositol 1,4,5-trisphosphate in permeabilized hepatocytes," <i>Biochem J.</i> , Vol. 284, pp. 507-512 (1992).	
		Rizzetto, M., et al., "Response of Pre-Core Mutant Chronic Hepatitis B Infection to Lamivudine," <i>Journal of Medical Virology</i> , Vol. 61, pp. 398-402 (2000).	
		Ryu, C. J., et al., "An 80-Kilodalton Protein That Binds to the Pre-S1 Domain of Hepatitis B Virus," <i>Journal of Virology</i> , Vol. 74, No. 1, pp. 110-116 (2000).	
		Saito, M., "OK-432, a killed streptococcal preparation, in the treatment of animal and human cancer and its mechanisms of action," <i>Forum on immunomodulators</i> , pp. 13-30. (1995)	
		Sardesai, V.M., "Role of Antioxidants in Health Maintenance," <i>Nutrition in Clinical Practice</i> , Vol. 10, pp. 19-25 (1995)	
		Schiff, E.R., "Lamivudine for Hepatitis B in Clinical Practice," <i>Journal of Medical Virology</i> , Vol. 61, pp. 386-391 (2000).	
		Sher, A., "Regulation of immunity to Parasites by T cells and T cell-derived cytokines," <i>Annu. Rev. Immunol.</i> , Vol. 10, pp. 385-409 (1992).	
		Sokolovsky, M., et al., "On the Synthesis of Cysteine Peptides," <i>J. Am. Chem. Soc.</i> , Vol. 86, pp. 1202-1206 (1963).	
		Suthanthiran, M., et al., "Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens," <i>Proc. Natl. Acad. Sci.</i> , Vol. 87, pp. 3343-3347 (1990).	
		Staal, F., et al., "Intracellular thiols regulate activation of nuclear factor kb and transcription of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 9943-9947 (1990).	
		Szent-Gyorgyi, A., "Charge Transfer and Electronic Mobility," <i>Biochemistry</i> , Vol. 58, pp. 2012-2014 (1967).	
		Takikawa, S., et al., "Cell Fusion Activity of Hepatitis C Virus Envelope Proteins," <i>Journal of Virology</i> , Vol. 74, No. 11, pp. 5066-5074 (2000).	
		Tam, J. P., "Synthesis of biologically active transforming growth factor alpha," <i>Int. J. Peptide Protein Res.</i> , Vol. 29, pp. 421-432 (1987).	
		Terradez, P., et al., "Depletion of tumour glutathione <i>in vivo</i> by buthionine sulphoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth," <i>Biochem. J.</i> , Vol. 292, pp. 447-483 (1993).	
		Tew, K. D., "Glutathione-associated Enzymes in Anticancer Drug Resistance," <i>Cancer Research</i> , Vol. 54, pp. 4313-4320 (1994).	
		Thomas, D. L., et al., "Determinants of the Quantity of Hepatitis C Virus RNA," <i>The Journal of Infectious Diseases</i> , Vol. 181, pp. 844-851 (2000).	
		Toyoda, H., et al., "Comparison of Characteristics Between Patients with GB Virus C/Hepatitis G Virus (GBV-C/HGV) RNA and those with GBV-C/HGV E2-Antibody in Patients with Hemophilia," <i>Journal of Medical Virology</i> , Vol. 60, pp. 34-38 (2000).	
		Trankmann, P., et al., "Einfluß der Substitution von Selen und Vitamin E auf Herzensuffizienz und ventrikuläre Herzrhythmusstörungen bei Patienten mit akutem Myokardinfarkt," <i>Medizinische Klinik</i> , Vol. 94, Suppl. III, pp. 78-80 (1999).	

/Jeffrey Russel/

07/18/2006



MAY 30 2006

FORM PTO-149/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
				FILING DATE: December 29, 2003	CONFIRMATION NO.: 2748
				APPLICANT: Kozhemyakin, et al.	
Sheet	6	of	6	GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel

OTHER ART — NON PATENT LITERATURE DOCUMENTS

JER	Westendorp, M. O., et al., "HIV-1 Tat potentiates TNF-induced NF- κ B activation and cytotoxicity by altering the cellular redox state," <i>The EMBO Journal</i> , Vol. 14, No. 3, pp. 546-554 (1995).	
	Whittington, R., et al., "Interleukin-2; A Review of its Pharmacological Properties and Therapeutic Use in Patients with Cancer," <i>Drugs</i> , Vol. 46, No. 3, pp. 446-514 (1993).	
	Yang, S.H., et al., "Internal Cleavage of Hepatitis C Virus NS3 Protein is Dependent on the Activity of NS34A Protease," <i>Virology</i> , Vol. 268, pp. 132-140 (2000).	
	Yao, N., et al., "Helicase, a target for novel inhibitors of hepatitis C virus," <i>Antiviral Therapy</i> , Vol. 3, pp. 93-97 (1998).	
	International Search Report dated 01/27/1997, PCT/RU96/00226.	
	International Search Report dated 05/27/1997, PCT/RU96/00340.	

EXAMINER: <i>/Jeffrey Russel/</i>	DATE CONSIDERED: 07/18/2006
--------------------------------------	--------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

O 15
JUL 03 2006
149/A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
		FILING DATE: 12/29/2003	CONFIRMATION NO.: 2748
		APPLICANT: L. Kozhemyakin et al.	
		GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel
Sheet	of		

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
JER		5,977,073		Khaled	11-02-1999

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)

EXAMINER: /Jeffrey Russel/	DATE CONSIDERED: 07/18/2006
----------------------------	-----------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]